Examine the data and tweets to deduce if the closing price of $bmy will boost or lower at 2017-06-12. Kindly confirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-05-26,0.7,1.6,-0.1,-0.8,-0.8,0.2,0.5,1.0,1.5,1.4,0.9
2017-05-30,0.0,0.6,-0.3,-0.1,-0.1,0.2,0.3,1.0,1.3,1.5,1.1
2017-05-31,0.4,0.7,-0.2,0.0,0.0,0.1,0.2,0.8,1.1,1.5,1.1
2017-06-01,-1.0,0.0,-1.2,1.1,1.1,-0.7,-0.8,-0.4,-0.0,0.5,0.1
2017-06-02,-0.5,0.4,-0.8,0.8,0.8,-1.3,-1.4,-1.2,-0.8,-0.4,-0.6
2017-06-05,2.7,3.8,-0.3,-4.7,-4.7,3.0,3.2,3.4,3.8,4.3,4.3
2017-06-06,1.2,1.4,-0.1,-1.3,-1.3,3.6,4.1,4.3,4.9,5.3,5.6
2017-06-07,-1.4,0.0,-1.9,1.8,1.8,1.2,2.0,2.3,2.9,3.3,3.7
2017-06-08,-0.5,1.0,-0.6,0.5,0.5,0.1,1.3,1.6,2.1,2.5,3.1
2017-06-09,-1.8,0.8,-2.0,1.7,1.7,-2.1,-0.6,-0.1,0.3,0.7,1.2

2017-05-26: AT_USER tic toc $nwbo collaborated with $bmy and $mrk because of this trial which reads out in a few weeks | members have an advantage. see track record  $bmy $pot $apa $cnq $ccl $ba| members have an 
2017-05-27: bristol-myers to hold investor teleconference on june 4 to review asco data  $bmy
2017-05-28: glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc got this one right, check date.|rt AT_USER introducing dcvax! $pbyi $fgen $icpt $bmy $mrk $kite $juno all good. but
2017-05-29: bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives 
2017-05-30: rt AT_USER top 50 disruptive tech!  1 cell coommands hundreds.  big $. $bmy $mrk $nvs $kite $juno $icpt $blue $celg $gild #cancer no e¡­|AT_USER well said roy the real question should be why did $bmy 
2017-05-31: 3 things in biotech you should learn today: may 31, 2017  $adxs $arry $bmy $invvy|commented on glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc|rt AT_USER $bmy and 
2017-06-01: rt AT_USER ubs:" immuno-oncology  drugs by target : $mrk $bmy $celg $incy $iph.pa $pfe $amgn $ziop $sgne $ino $clsn ..." |rt AT_USER peruvian lawmakers seek a compulsory license for a bristol-myers hi
2017-06-02: AT_USER keytruda is kicking opdivos ass.  if $bmy  was smart they buy them n do a combo pill.  like $nvs or mrk did|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $
2017-06-03: amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study  $amgn $bmy #sitifatimah ¡­|amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stag
2017-06-04: cowen pd-1/pd-l1 market opportunity to exceed $32b in 2022 $mrk $bmy $rog $azn |rt AT_USER keynote-059 keytruda monotherapy arm in &gt;3l gastric cancer, via c fuchs $mrk $bmy #asco17 |rt AT_USER we'r
2017-06-05: bristol-myers squibb's opdivo, yervoy put the brakes on mesothelioma in phase 2  $bmy #asco17|tuesday: $tho, $acor, $rh, $tsla, $panw, $vmw, $bmy|rt AT_USER on the fly: top stock stories at midday $aa
2017-06-06: rt AT_USER bms' opdivo, merck's keytruda lead their class in cancer vaccine combo studies: report  $bmy $mrk|rt AT_USER they key on the $bmy lag3 data is the high lag3 expressers. 5 of 6 responses in 
2017-06-07: rt AT_USER with asco data tallied, bristol-myers loses ground to merck in i-o field  $bmy $mrk|current positions in the live mentorship program options trading account. $cmcsa $tsla $pypl $bx $jnj $bm
2017-06-08: rt AT_USER bristol myers $bmy iv rallied late day with 3,000 december $60 calls bought to open $0.95, opening put seller june 2018 to¡­|$bmy is in stochastic oversold  winning 61.40% in the past. |#br
2017-06-09: rt AT_USER AT_USER AT_USER $kite $juno $amgn $nvs $bmy $mrk #dcvax will disrupt all. $nwbo $blue $celg $sgen $loxo #pem¡­|rt AT_USER AT_USER AT_USER $kite $juno $amgn $nvs $bmy $mrk #dcvax will disrup
2017-06-10: bristol-myers squibb co $bmy stock rating upgraded by bidaskclub |bristol-myers squibb co $bmy raised to hold at bidaskclub |bristol-myers squibb co $bmy upgraded to hold by bidaskclub  #stocks|bristo
2017-06-11: rt AT_USER the $bmy cancer yo-yo, and a setback that leaves it vulnerable to takeover talk. by AT_USER  v¡­|$ibb stong most of the day, closed weak, still watching for roation. select names have been 
Answer:
date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-05-26,0.7,1.6,-0.1,-0.8,-0.8,0.2,0.5,1.0,1.5,1.4,0.9
2017-05-30,0.0,0.6,-0.3,-0.1,-0.1,0.2,0.3,1.0,1.3,1.5,1.1
2017-05-31,0.4,0.7,-0.2,0.0,0.0,0.1,0.2,0.8,1.1,1.5,1.1
2017-06-01,-1.0,0.0,-1.2,1.1,1.1,-0.7,-0.8,-0.4,-0.0,0.5,0.1
2017-06-02,-0.5,0.4,-0.8,0.8,0.8,-1.3,-1.4,-1.2,-0.8,-0.4,-0.6
2017-06-05,2.7,3.8,-0.3,-4.7,-4.7,3.0,3.2,3.4,3.8,4.3,4.3
2017-06-06,1.2,1.4,-0.1,-1.3,-1.3,3.6,4.1,4.3,4.9,5.3,5.6
2017-06-07,-1.4,0.0,-1.9,1.8,1.8,1.2,2.0,2.3,2.9,3.3,3.7
2017-06-08,-0.5,1.0,-0.6,0.5,0.5,0.1,1.3,1.6,2.1,2.5,3.1
2017-06-09,-1.8,0.8,-2.0,1.7,1.7,-2.1,-0.6,-0.1,0.3,0.7,1.2

2017-05-26: AT_USER tic toc $nwbo collaborated with $bmy and $mrk because of this trial which reads out in a few weeks | members have an advantage. see track record  $bmy $pot $apa $cnq $ccl $ba| members have an 
2017-05-27: bristol-myers to hold investor teleconference on june 4 to review asco data  $bmy
2017-05-28: glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc got this one right, check date.|rt AT_USER introducing dcvax! $pbyi $fgen $icpt $bmy $mrk $kite $juno all good. but
2017-05-29: bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives 
2017-05-30: rt AT_USER top 50 disruptive tech!  1 cell coommands hundreds.  big $. $bmy $mrk $nvs $kite $juno $icpt $blue $celg $gild #cancer no e¡­|AT_USER well said roy the real question should be why did $bmy 
2017-05-31: 3 things in biotech you should learn today: may 31, 2017  $adxs $arry $bmy $invvy|commented on glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc|rt AT_USER $bmy and 
2017-06-01: rt AT_USER ubs:" immuno-oncology  drugs by target : $mrk $bmy $celg $incy $iph.pa $pfe $amgn $ziop $sgne $ino $clsn ..." |rt AT_USER peruvian lawmakers seek a compulsory license for a bristol-myers hi
2017-06-02: AT_USER keytruda is kicking opdivos ass.  if $bmy  was smart they buy them n do a combo pill.  like $nvs or mrk did|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $
2017-06-03: amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study  $amgn $bmy #sitifatimah ¡­|amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stag
2017-06-04: cowen pd-1/pd-l1 market opportunity to exceed $32b in 2022 $mrk $bmy $rog $azn |rt AT_USER keynote-059 keytruda monotherapy arm in &gt;3l gastric cancer, via c fuchs $mrk $bmy #asco17 |rt AT_USER we'r
2017-06-05: bristol-myers squibb's opdivo, yervoy put the brakes on mesothelioma in phase 2  $bmy #asco17|tuesday: $tho, $acor, $rh, $tsla, $panw, $vmw, $bmy|rt AT_USER on the fly: top stock stories at midday $aa
2017-06-06: rt AT_USER bms' opdivo, merck's keytruda lead their class in cancer vaccine combo studies: report  $bmy $mrk|rt AT_USER they key on the $bmy lag3 data is the high lag3 expressers. 5 of 6 responses in 
2017-06-07: rt AT_USER with asco data tallied, bristol-myers loses ground to merck in i-o field  $bmy $mrk|current positions in the live mentorship program options trading account. $cmcsa $tsla $pypl $bx $jnj $bm
2017-06-08: rt AT_USER bristol myers $bmy iv rallied late day with 3,000 december $60 calls bought to open $0.95, opening put seller june 2018 to¡­|$bmy is in stochastic oversold  winning 61.40% in the past. |#br
2017-06-09: rt AT_USER AT_USER AT_USER $kite $juno $amgn $nvs $bmy $mrk #dcvax will disrupt all. $nwbo $blue $celg $sgen $loxo #pem¡­|rt AT_USER AT_USER AT_USER $kite $juno $amgn $nvs $bmy $mrk #dcvax will disrup
2017-06-10: bristol-myers squibb co $bmy stock rating upgraded by bidaskclub |bristol-myers squibb co $bmy raised to hold at bidaskclub |bristol-myers squibb co $bmy upgraded to hold by bidaskclub  #stocks|bristo
2017-06-11: rt AT_USER the $bmy cancer yo-yo, and a setback that leaves it vulnerable to takeover talk. by AT_USER  v¡­|$ibb stong most of the day, closed weak, still watching for roation. select names have been 